NewLink Genetics Corporation (NASDAQ:NLNK) has tumbled 8.95% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 0.59% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.85%. NewLink Genetics Corporation (NASDAQ:NLNK) has underperformed the index by 0.33% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
NewLink Genetics Corporation (NASDAQ:NLNK): The stock opened at $10.73 on Friday but the bulls could not build on the opening and the stock topped out at $10.97 for the day. The stock traded down to $10.11 during the day, due to lack of any buying support eventually closed down at $10.28 with a loss of -3.66% for the day. The stock had closed at $10.67 on the previous day. The total traded volume was 2,227,734 shares.
The company shares have dropped -77.95% from its 1 Year high price. On Aug 18, 2015, the shares registered one year high at $56.16 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $12.01 and the 200 Day Moving Average price is recorded at $21.32.
On the companys insider trading activities, Talarico Ernest Iii, director of Newlink Genetics Corp had purchased 4,065 shares on June 6, 2016 in a transaction. The price per share was $12.32 and the total amount of the disclosed transaction was $50,081.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Many analysts have stated their opinion on the company shares. Brokerage firm SunTrust Robinson Humphrey downgrades its rating on NewLink Genetics Corporation (NASDAQ:NLNK). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on May 11, 2016. Currently the company Insiders own 12% of NewLink Genetics Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -1.85% . Institutional Investors own 58.47% of NewLink Genetics Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -18.06%.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune systems tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.